51 results about "TB - Tuberculosis" patented technology

The invention discloses a pulmonary tuberculosis focus map segmentation system based on symmetric similarity and dynamic sample amplification, which comprises a sternum suppression network module, an entropy-driven sample number dynamic amplification module, a pulmonary tuberculosis focus detection module and a sternum suppression network module, and is used for removing a sternum image in a chest X-ray map; the entropy-driven sample dynamic amplification module is used for carrying out dynamic amplification on the number of sample images based on the complexity of the image and the existing training state of the model for a single image; specifically, for each image, an information entropy is calculated for probability distribution output by a model of each training round; in the early stage of training, the number of training image samples is amplified slightly, and the number of amplified samples is increased along with model training; and the pulmonary tuberculosis focus detection module is used for designing a pulmonary tuberculosis focus detection network model by using the target detector and the symmetric similarity of the pulmonary tuberculosis images, and segmenting a tuberculosis focus map from the X-ray map.

This invention discloses a device and its application for distinguishing between pneumonia and tuberculosis in children. By detecting S100A8 / A9 and determining the corresponding diagnostic threshold, this invention achieves rapid, sensitive, and specific differentiation between children with tuberculosis and normal children, as well as children with pneumonia caused by other pathogens. It provides a reliable basis for clinical auxiliary diagnosis, improves diagnostic efficiency and accuracy, avoids misdiagnosis and missed diagnosis, and can thus guide rational clinical treatment and improve patient prognosis.

The invention relates to tuberculosis early warning, in particular to an early warning management method for suspected tuberculosis cases, which comprises the following steps of: carrying out standardized coding system design on a pulmonary tuberculosis examination institution, a jurisdiction fixed-point institution, a jurisdiction fixed-point institution department, a jurisdiction fixed-point institution doctor and an early warning management system workstation, and carrying out warehousing management on related information; setting a database table and a corresponding index; determining a contrast relationship between the pulmonary tuberculosis examination institution and the jurisdiction fixed-point institution, and a logic relationship between a jurisdiction fixed-point institution department to which a jurisdiction fixed-point institution doctor belongs and an early warning management system workstation to which the jurisdiction fixed-point institution department belongs; when the pulmonary tuberculosis examination institution judges that a suspected tuberculosis case appears, early warning bubbles are pushed through an early warning management system work station to remind a designated jurisdiction fixed-point institution department and a designated jurisdiction fixed-point institution doctor, and whole-process state management is carried out; according to the technical scheme provided by the invention, the defect that efficient early warning management is difficult to carry out on suspected tuberculosis cases in the prior art can be effectively overcome.

According to the invention, 23 key miRNAs are identified in patients with liver injury caused by taking antituberculous drugs. Compared with patients who cannot cause liver injury by taking antituberculous drugs, the miRNAs are obviously differentially expressed in the patients who cannot cause liver injury by taking antituberculous drugs. Furthermore, five miRNAs are selected from the key miRNAs to construct a diagnosis model for drug-induced liver injury caused by tuberculosis and antituberculosis drugs. The model can accurately diagnose tuberculosis, and also can accurately diagnose drug-induced liver injury caused by antituberculosis drugs.

Methods for treating tuberculosis are provided.

A set of serum metabolic biomarkers and detection kit for detecting drug-resistant tuberculosis are provided. The set of the serum metabolic biomarkers includes 17 serum metabolic biomarkers. The 17 serum metabolic biomarkers are verified to be associated with tuberculosis based on the level changes of these biomarkers. The 17 metabolites includes taurine, homocysteine, uric acid, ascorbic acid, suberylglycine, uridine, dopamine 4-sulfate, inosinic acid, glyceraldehyde phosphate, [3-methoxy-4-(phosphoryl)phenyl]carbonyl sulfonic acid, nuclomedone, n4-cyclopropyl-6-(2,3-dichlorophenyl)-1,2,3,4-tetrahydropyrimidine-2,4-diimine, 1-[2-chlorine-2-(2,4-dichlorophenyl)ethenyl]-1,2,4-triazole, tetrachloro-phthalic anhydride, malotilate, fulvic acid, and L-neopterin. The serum metabolic biomarkers and detection kit for detecting drug-resistant tuberculosis can assist doctors in accurately diagnosing the disease, which is of great significance for the diagnosis and mass screening for drug-resistant tuberculosis.

This invention discloses miRNA biomarkers for the auxiliary diagnosis of tuberculosis and their applications. This invention claims protection for the use of substances for detecting miRNAs in serum exosomes in the preparation of products; the purpose of said products is for the diagnosis or auxiliary diagnosis of tuberculosis patients or for the diagnosis or auxiliary diagnosis of active pulmonary tuberculosis patients. The miRNAs are any one or any combination of the following five miRNAs: miR-28-3p, miR-193b-5p, miR-370-3p, miR-1246, and miR-2110. This invention also claims protection for the use of substances for detecting serum exosome miRNAs in the preparation of products; the purpose of said products is for the diagnosis or auxiliary diagnosis of latent tuberculosis infection. The miRNAs are any one or any combination of the following three miRNAs: let-7e-5p, let-7d-5p, and miR-140-5p. This invention lays the foundation for further development of rapid early diagnosis techniques and methods for tuberculosis.

The invention relates to a compound for preventing or treating tuberculosis (TB) or an acceptable salt of the compound, and the compound is shown as a general formula (I).

The application provides a biomarker composition for diagnosing tuberculosis, the biomarker composition screened by the application can be used for diagnosing tuberculosis, and the area under the ROC curve (AUC) of the model for diagnosing tuberculosis is greater than 0.9, when the cut-off value (diagnosis threshold value) is 0.696, the sensitivity and specificity of diagnosis are both greater than 80%.

The invention discloses a spinal tuberculosis auxiliary diagnosis method and system, and relates to the technical field of intelligent medical treatment. The method comprises the following steps: acquiring a spinal tuberculosis DR image to be diagnosed; performing a preprocessing operation on the DR image to reduce image noise and enhance a spine structure contrast; inputting the preprocessed DR image into a pre-trained spinal tuberculosis classification model to obtain prediction probability distribution and confidence evaluation of the spinal tuberculosis physical classification; inputting the preprocessed DR image into a pre-trained focus detection model to obtain spatial position positioning information of the spinal tuberculosis focus; and integrating the prediction probability distribution, confidence evaluation and spatial position positioning information to generate an auxiliary diagnosis report. Under the condition of low-quality DR images in primary hospitals, primary doctors can be assisted in improving the diagnosis accuracy and positioning precision of early spinal tuberculosis lesions.

The invention discloses a three-gene combination, a primer probe set and a system for qPCR (quantitative polymerase chain reaction) rapid screening of tuberculosis progression risk and application of the three-gene combination, the primer probe set and the system. The method comprises the following steps: firstly, screening out candidate genes APOL1, C1QC and SOCS1 which are stable across time windows and have high prediction performance; then a three-gene combination scoring you model (PRI3) composed of APOL1, C1QC and SOCS1 is constructed and used for predicting the risk that a latent tuberculosis infected individual progresses into active tuberculosis within a set time window; the method comprises the following steps of: firstly, selecting a reference model (RISK6, Sweeney3, Gliddon4 and BATF2), then performing performance verification in an independent verification queue, and comparing with the existing reference model (RISK6, Sweeney3, Gliddon4 and BATF2), and the result shows that the scoring model disclosed by the invention can keep stable performance in adult population and multiple time windows (such as 0-6 months, 0-12 months and 0-24 months). The scheme of the invention is suitable for crowd screening, disease early warning and individualized intervention decision.

The invention provides an abdominal tuberculosis image processing method, and relates to the technical field of image processing and medical image analysis. The method comprises the following specific steps: collecting an abdominal tuberculosis image, making a data set, preprocessing the image, establishing a multi-scale convolution module, establishing a multi-scale pooling module, optimizing a feature fusion module, establishing a classification prediction module, constructing an abdominal tuberculosis image processing model, and training and detecting the abdominal tuberculosis image processing model. According to the method, an adaptive enhancement mechanism and a noise suppression strategy are introduced to pre-process an image data set, a multi-scale convolution module and a pooling module are designed to realize multi-scale feature extraction and fusion, low-frequency and high-frequency information fusion and an adaptive weighting mechanism are adopted to optimize image feature processing, and a plurality of modules act synergistically to realize multi-scale feature extraction and fusion. The processing efficiency and the classification precision of the abdominal tuberculosis image are remarkably improved, and particularly, the method shows relatively high robustness and adaptability in image analysis of different tuberculosis change stages.

The invention relates to a T cell intracellular factor composition and application thereof, the T cell intracellular factor composition is selected from multiple of CCL3, CCL4, IFN gamma and TNFa, and the expression levels of the CCL3, the CCL4, the IFN gamma and the TNFa in peripheral blood of active tuberculosis patients are obviously different. As the expression levels in the peripheral blood of the active tuberculosis patient are obviously different, different stages and health states of tuberculosis can be accurately distinguished, the accuracy and specificity of diagnosis are obviously improved, and a reliable basis is provided for clinical diagnosis.

The application discloses a combination of three lncRNA markers for screening tuberculosis patients and application thereof. The application provides application of a substance for detecting marker 1, a substance for detecting marker 2 and a substance for detecting marker 3 in preparation of a kit for screening tuberculosis patients. The application also provides application of the marker 1, the marker 2 and the marker 3 as combined markers in development of a kit for screening tuberculosis patients. The marker 1 is lncRNA 046173 or a characteristic fragment of the lncRNA 046173. The marker 2 is lncRNA PRDM7-1:2 or a characteristic fragment of the lncRNA PRDM7-1:2. The marker 3 is lncRNA CHI3L1-2:3 or a characteristic fragment of the lncRNA CHI3L1-2:3. The three lncRNAs have more excellent performance as combined diagnostic markers. The application is very important for rapid diagnosis and early treatment of tuberculosis.

Provided is a compound for preventing or treating tuberculosis (TB) or an acceptable salt thereof, the compound being represented by general formula (I).

The invention belongs to the technical field of sample split charging, and particularly relates to tuberculosis sample automatic split charging and label printing equipment which comprises a supporting base and a split charging sleeve box, a split charging table is fixedly connected to the supporting base, a conveying mechanism is arranged on the split charging table, and a first mounting plate and a second mounting plate are fixedly connected to the split charging table; the first mounting plate and the second mounting plate are symmetrically arranged, the first mounting plate and the second mounting plate are located on the two sides of the sub-packaging table respectively, three sub-packaging assemblies which are symmetrically arranged are arranged between the first mounting plate and the second mounting plate, and each sub-packaging assembly comprises two sub-packaging suites which are symmetrically arranged. According to the tuberculosis sample subpackaging device, the contact time of medical workers and tuberculosis samples can be shortened, the infection risk is reduced, the specialized medical workers do not need to discriminate and subpackage the samples in the subpackaging process, meanwhile, the sample leakage harm caused by misoperation of operators can be reduced, and the safety coefficient of tuberculosis sample subpackaging and label printing is improved.

The invention discloses a lipid biomarker for tuberculosis-coronary heart disease co-diagnosis and application of the lipid biomarker. Lipid is any one or a combination of LPC (O-22: 1), PI (10: 016: 0) or PC (10: 018: 0). The lipid biomarker provided by the invention can be used for early diagnosis of tuberculosis-coronary heart disease patients of tuberculosis patients, and may become an intervention target for preventing tuberculosis from developing into tuberculosis-coronary heart disease co-diseases.

This invention relates to the field of biological sample preservation technology, specifically to a room-temperature preservation solution for bacterial RNA from sputum samples of tuberculosis patients. Each 100 mL of the RNA preservation solution comprises the following ingredients: 2-5 g tris(hydroxymethyl)aminomethane, 0.5-1.3 g mucin digester, 20-30 g guanidine isothiocyanate, 0.1-0.3 g hexadecylpyridine chloride, 0.5-1.2 g ethylhexene dicysteine, 20-40 mL fixative, 1-5 g stabilizer, 0.1-0.5 g inorganic salt, 0.3-0.6 g surfactant, and 0.1-0.5 g preservative. The preservation solution provided by this invention can effectively liquefy sputum samples at room temperature, meeting the requirements for long-distance sample transportation. The RNA quality of sputum samples treated with the preservation solution of this invention is suitable for various subsequent molecular detection methods, possessing significant application value and promising prospects for widespread application.

A chrysin derivative and a composition for a treatment of tuberculosis containing the same are provided. In detail, a chrysin derivative compound represented by chemical formula 1,or a salt thereof, and a composition for a treatment of tuberculosis and inflammation containing the same as an active ingredient are provided. In chemical formula 1, at least one of R1 and R2 is hydrogen, and the other is a C1-6 hydroxyalkyl group or a C1-10 alkenyl group unsubstituted or substituted with one or more C1-10 alkyl groups

The invention relates to the technical field of biological medicines, and discloses application of an IGF1R (Insulin-like Growth Factor 1 Receptor) gene as an anti-tuberculosis target spot in treatment and / or diagnosis of tuberculosis. The IGF1R gene is related to the susceptibility of tuberculosis. The IGF1R gene is used for regulating a tumor-related pathway and a PI3K-Akt signal pathway, so that host-oriented anti-tuberculosis is realized. BEAS-2B cells are stimulated through PPD, it is proved that the IGF1R gene has susceptibility correlation with TB, the correlation between the IGF1R gene and a tumor-related pathway and a PI3K-Akt signal pathway and related key functional genes are determined, a new thought is provided for research on TB morbidity and tuberculosis susceptibility, and a foundation is laid for the IGF1R gene serving as a new target in TB diagnosis and treatment.

The application belongs to the technical field of medical diagnosis, and specifically discloses a diabetes mellitus combined with tuberculosis marker and application thereof. It is found for the first time that the transcription level and protein level of activin A receptor 2A (ACVR2A), angiostatin and chemokine ligand 14 (CXCL14) are inversely proportional to the severity of diabetes mellitus combined with tuberculosis, and can be used as a diabetes mellitus combined with tuberculosis marker to indirectly reflect whether the crowd is suffering from diabetes mellitus combined with tuberculosis and the development of the disease, so as to timely diagnose and treat. A new diabetes mellitus combined with tuberculosis detection kit can be prepared according to the three markers, and is applied to public medical treatment. The three markers can effectively improve the diagnosis efficiency of diabetes mellitus combined with tuberculosis, and have high sensitivity and strong specificity.

This invention provides the use of SE-DR (HLA-DR molecule containing a co-epitope) affinity peptides for the preparation of drugs to treat rheumatic diseases in rheumatoid arthritis patients who are tuberculosis-positive and / or have hepatitis B. [Solution] The present invention provides a pharmaceutical composition comprising an SE-DR affinity peptide and a non-antigen-specific antirheumatic drug, and the use thereof for the preparation of drugs for the treatment of various types of rheumatic diseases. The pharmaceutical composition can rapidly inhibit the progression of rheumatic diseases and achieve sustained remission even after tapering or discontinuation of the drug, for complete control of rheumatic diseases.

Disclosed herein is a method of treating cachexia in a subject. According to some embodiments of the present disclosure, the method includes administering to the subject an effective amount of a recombinant antibody or a fragment thereof, which exhibits a binding affinity and a neutralizing effect on parathyroid hormone-related protein. According to certain embodiments of the present disclosure, the cachexia is caused by a parathyroid hormone-related protein (PTHrP)-expressing cancer, chronic kidney disease, kidney failure, heart failure, or tuberculosis.

The invention discloses a combined marker for risk assessment of active tuberculosis and application of the combined marker. The combined marker comprises interleukin 6, a chemotactic factor ligand 9, a chemotactic factor ligand 10 and a vascular endothelial growth factor. According to the disclosure, the combined marker for evaluating the risk of active tuberculosis of the subject and the application thereof can be provided.

The invention relates to the technical field of biomedicine, in particular to application of a gene marker for risk assessment of active tuberculosis of an HIV infected person. According to the application of the provided quantitative detection reagent of the gene marker in preparation of a product for evaluating the risk of the HIV infected person suffering from the active tuberculosis, the gene marker shown as Seq.No1-6 comprises one or more of BEX5, CEL, DUSP14, EIF3I, PPFIA4 and TSEN2, and the gene marker shown as Seq.No1-6 comprises one or more of BEX5, CEL, DUSP14, EIF3I, PPFIA4 and TSEN2. According to the application, the problem of identifying active tuberculosis high-risk groups in HIV infected persons is solved from the gene level, the disease progress trend can be captured earlier and more accurately from the gene level, and a foundation is laid for targeted implementation of tuberculosis preventive treatment.

The application belongs to the field of biomedicine and particularly relates to a group of biomarkers for diagnosing subclinical tuberculosis. The application discloses a group of biomarkers for diagnosing subclinical tuberculosis, and a group of plasma protein marker combinations for diagnosing subclinical tuberculosis are screened out by Olink technology. The biomarkers can significantly distinguish subclinical TB from healthy+LTBI samples, and have high diagnostic efficiency for subclinical tuberculosis alone or in combination, which is helpful to promote early intervention and treatment of tuberculosis. The AUC values of EN-RAGE and EN-RAGE for single diagnosis are both greater than 0.8, and the AUC value of the combination of EN-RAGE and MCP-3 for joint diagnosis is 0.896.

Prophylaxis, immune therapy and vaccine strategies for Covid-19 variants and comorbid conditions such as aging, diabetes, cancer, tuberculosis or HIV. In one mode of invention, the role of the C3 Amplification loop is defined and how it derails the SNS functions or immune function at fluid and tissue levels. The plasticity in subverting C3 amplification control mechanism contribute to survival strategies of SARS-CoV-2 that contributes to various variants that can be reactivated at any stage of life based on immune system of patient that may get compromised with comorbid diseases such as aging, diabetes, cancer and HIV. Therapeutic modulation takes into consideration plasticity of different patient needs and their comorbid conditions by developing varying formulation methods and its combination approaches.

The application belongs to the technical field of biological medicine, and particularly relates to application of a benzimidazole compound in preparation of anti-tuberculosis drugs. The benzimidazole compound can target into a macrophage nuclear receptor coactivator 4 molecule, combine with the macrophage nuclear receptor coactivator 4, thereby inhibiting the combination of ferritin heavy chain and the macrophage nuclear receptor coactivator 4, promoting the accumulation of the macrophage ferritin heavy chain, inhibiting the degradation of the ferritin heavy chain, and thereby inhibiting the proliferation of tubercle bacillus. The benzimidazole compound has significant anti-tubercle bacillus activity and the effect of treating tuberculosis.

The application discloses application of lncRNA PRDM7-1:2 as a marker in development of a tuberculosis patient screening reagent. The application provides application of a substance for detecting lncRNA PRDM7-1:2 or a characteristic fragment of lncRNA PRDM7-1:2 in preparation of a kit for screening tuberculosis patients or in preparation of a kit for diagnosing or assisting in diagnosing tuberculosis. The inventors have carried out whole genome RNA chip screening, completed lncRNA spectrum screening and comparative analysis in PBMCs from two types of people, i.e. tuberculosis patients and healthy people, and preliminarily obtained a large number of differentially expressed lncRNAs. The inventors have carried out qPCR verification on the preliminarily obtained lncRNAs in another independent sample, and screened two lncRNAs. The inventors have analyzed the performance of the two lncRNAs as separate markers in a new population. The application is very important for rapid diagnosis of tuberculosis and early treatment.

Use of nintedanib or a medicinal salt thereof for the manufacture of a drug for treating tuberculosis, wherein the nintedanib or a medicinal salt thereof is used in combination with another antituberculous drug to treat tuberculosis or as an adjunct to tuberculosis treatment, the other antituberculous drug being selected from rifampicin, isoniazid, pyrazinamide, ethambutol, fluoroquinolones, streptomycin, kanamycin, amikacin, capreomycin, sodium 4-aminosalicylate, ethionamide, cycloserine, clofazimine, and linezolid.